Advertisement
Cancer Discovery Impact Factor 2022: Deciphering the Journal's Influence
The fight against cancer is a relentless pursuit of knowledge, driven by groundbreaking research and innovative discoveries. At the forefront of this battle lies Cancer Discovery, a prestigious journal publishing cutting-edge findings in oncology. Understanding its impact factor is crucial for researchers, clinicians, and anyone invested in the future of cancer treatment and prevention. This comprehensive guide dives deep into the Cancer Discovery impact factor for 2022, exploring its significance, contributing factors, and implications for the field of cancer research. We'll also examine how the impact factor is calculated and what it means for the future of publications within the journal.
Understanding the Impact Factor: A Crucial Metric
Before delving into the specific Cancer Discovery impact factor for 2022, it's crucial to understand what an impact factor represents. Simply put, it's a measure reflecting the average number of citations received by articles published in a particular journal during a specific period (typically the two preceding years). A higher impact factor generally indicates greater influence and prestige within the scientific community. This influence stems from several factors, including the journal's rigor in peer review, the significance of the research it publishes, and the overall visibility and reach of the journal itself. In the competitive landscape of scientific publishing, the impact factor serves as a significant benchmark for researchers seeking to publish their work in high-impact journals.
Cancer Discovery Impact Factor 2022: The Numbers and Their Implications
While the precise 2022 impact factor for Cancer Discovery needs to be sourced from official reporting agencies like Clarivate Analytics' Journal Citation Reports (JCR), we can analyze the trends and factors contributing to its likely high value. Historically, Cancer Discovery has consistently maintained a high impact factor, reflecting its commitment to publishing impactful research at the forefront of cancer biology and treatment. The journal's rigorous peer-review process, combined with its focus on high-quality, original research, ensures only the most significant and impactful findings are published.
The impact factor’s significance extends beyond a mere number. A high impact factor translates into increased visibility for published research, attracting attention from other scientists, clinicians, and the wider scientific community. This leads to broader dissemination of knowledge, increased collaboration opportunities, and ultimately, faster progress in cancer research and treatment.
Factors Influencing the Cancer Discovery Impact Factor
Several key elements contribute to the high impact factor of Cancer Discovery:
Rigorous Peer Review: The journal employs a stringent peer-review process, ensuring that only high-quality, original research meets its publication standards. This process involves critical evaluation by experts in the field, guaranteeing the validity and reliability of published studies.
Focus on Translational Research: Cancer Discovery prioritizes research with clear translational potential, meaning studies that can directly lead to improvements in cancer diagnosis, treatment, or prevention. This focus on practical applications significantly elevates the journal's impact within the medical community.
Multidisciplinary Approach: The journal embraces a multidisciplinary approach, publishing research from various fields relevant to cancer research, including oncology, genetics, immunology, and bioengineering. This broad scope enhances the journal's appeal and attracts contributions from a wider range of experts.
High Visibility and Accessibility: Cancer Discovery's online presence and accessibility through various platforms ensure its research reaches a vast audience globally. This wide dissemination of knowledge is a key driver of its high impact factor.
Impactful Research Published: Ultimately, the most significant contributor is the quality and impact of the research itself. The journal consistently publishes groundbreaking studies that significantly advance the understanding of cancer biology and its treatment.
The Impact Factor's Role in the Future of Cancer Research
The Cancer Discovery impact factor, and the impact factors of other leading journals, serves as a barometer of the field's progress. A high impact factor demonstrates the ongoing vitality and innovation within cancer research. It attracts top researchers, facilitates collaboration, and encourages further investment in this crucial area of scientific inquiry. In essence, a high impact factor serves as a catalyst for accelerated progress against cancer.
Article Outline: Cancer Discovery Impact Factor 2022
Article Title: Cancer Discovery Impact Factor 2022: Deciphering the Journal's Influence
Outline:
Introduction: Hooking the reader and providing an overview of the topic.
Chapter 1: Understanding the Impact Factor: Explaining the concept and its significance in scientific publishing.
Chapter 2: Cancer Discovery Impact Factor 2022: Analyzing the numbers (once available from official sources) and its implications.
Chapter 3: Factors Influencing the Impact Factor: Discussing the contributing elements, such as peer review, research focus, and accessibility.
Chapter 4: The Impact Factor's Role in the Future of Cancer Research: Exploring the long-term significance of the impact factor.
Conclusion: Summarizing the key findings and emphasizing the importance of the journal's influence.
FAQs: Answering frequently asked questions about the impact factor and Cancer Discovery.
Related Articles: Listing and briefly describing relevant articles.
(The above outline has been expanded upon within the main body of this article.)
FAQs
1. Where can I find the official 2022 impact factor for Cancer Discovery? The official impact factor will be available through the Journal Citation Reports (JCR) published by Clarivate Analytics.
2. What is the significance of a high impact factor for a journal like Cancer Discovery? A high impact factor indicates the journal publishes influential research widely cited by other scientists, signifying its prestige and influence within the field.
3. How is the impact factor calculated? It's calculated by dividing the number of citations received by articles published in the journal during the two preceding years by the total number of citable articles published during those same years.
4. Does a high impact factor guarantee the quality of individual research papers? No, the impact factor is a journal-level metric. While it suggests high-quality overall, individual papers still need to be critically evaluated.
5. What are some limitations of using the impact factor as a sole measure of journal quality? The impact factor can be influenced by factors like publication bias, self-citation, and the field's overall citation practices.
6. How does the impact factor of Cancer Discovery compare to other oncology journals? This requires comparison with the impact factors of other top oncology journals, readily available on the JCR.
7. What role does the peer-review process play in maintaining Cancer Discovery's high impact factor? Rigorous peer review ensures the quality and validity of published research, directly influencing its subsequent citation rate.
8. How does the accessibility of Cancer Discovery contribute to its impact factor? Wide online access and dissemination of articles ensure broad readership and potential for citation, boosting the impact factor.
9. What are the future implications of Cancer Discovery's impact factor for cancer research? A consistently high impact factor attracts leading researchers, enhancing collaboration and accelerating progress in cancer research.
Related Articles:
1. The Role of Open Access in Increasing the Impact of Cancer Research: Discusses how open access publication models can enhance the reach and impact of cancer research findings.
2. Citation Analysis of Cancer Research: Trends and Patterns: Analyzes citation trends in cancer research to identify impactful areas and influential publications.
3. Impact Factors and the Evaluation of Scientific Journals: A Critical Perspective: Critically examines the use of impact factors as a sole measure of scientific journal quality.
4. Cancer Research Funding and its Impact on Publication Output: Investigates the relationship between research funding and the number and quality of publications in cancer research.
5. The Importance of Multidisciplinary Collaboration in Cancer Research: Highlights the benefits of collaboration across various scientific disciplines to address complex cancer challenges.
6. Translational Research in Oncology: Bridging the Gap Between Bench and Bedside: Discusses the importance of translating basic research findings into practical clinical applications for cancer patients.
7. Ethical Considerations in Cancer Research Publication: Explores ethical issues related to research integrity, authorship, and conflicts of interest in cancer research publications.
8. The Future of Cancer Research: Emerging Trends and Technologies: Examines cutting-edge technologies and research areas poised to revolutionize cancer treatment and prevention.
9. Metrics Beyond Impact Factor: Assessing the true value of scientific journals: Explores alternative metrics for evaluating the quality and influence of scientific publications beyond the impact factor.
| cancer discovery impact factor 2022: Cancer Evolution Charles Swanton, 2017 Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This process, termed clonal evolution, can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts. Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines cancer progression as an evolutionary process and explores how this way of looking at cancer may lead to more effective strategies for managing and treating it. The contributors review efforts to characterize the subclonal architecture and dynamics of tumors, understand the roles of chromosomal instability, driver mutations, and mutation order, and determine how cancer cells respond to selective pressures imposed by anticancer agents, immune cells, and other components of the tumor microenvironment. They compare cancer evolution to organismal evolution and describe how ecological theories and mathematical models are being used to understand the complex dynamics between a tumor and its microenvironment during cancer progression. The authors also discuss improved methods to monitor tumor evolution (e.g., liquid biopsies) and the development of more effective strategies for managing and treating cancers (e.g., immunotherapies). This volume will therefore serve as a vital reference for all cancer biologists as well as anyone seeking to improve clinical outcomes for patients with cancer. |
| cancer discovery impact factor 2022: Tertiary Lymphoid Structures Marie-Caroline Dieu-Nosjean, 2018-09-05 This volume explores the various methods used to study tertiary lymphoid structures (TLS) in pathological situations. Pre-clinical models are also discussed in detail to show how TLS structure, development, and maintenance can be targeted and studied in vivo. The chapters in this book cover topics such as humans and mice; strategies to quantify TLS in order to use it in stained tissue sections; classifying a gene signature form fixed and paraffin-embedded tissues; and development of murine inflammatory models to help look at TLS in the context of infection or malignancy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and thorough, Tertiary Lymphoid Structures: Methods and Protocols is a valuable resource that increases the reader’s knowledge on immune functions and how they will pave the way to future therapeutic applications. |
| cancer discovery impact factor 2022: How Tobacco Smoke Causes Disease United States. Public Health Service. Office of the Surgeon General, 2010 This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products. |
| cancer discovery impact factor 2022: AJCC Cancer Staging Manual Frederick L, Greene, David L. Page, Irvin D. Fleming, April G. Fritz, Charles M. Balch, Daniel G. Haller, Monica Morrow, 2013-11-21 The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms. |
| cancer discovery impact factor 2022: Current Trends in Cancer Research , 1964 |
| cancer discovery impact factor 2022: Paclitaxel Mallappa Kumara Swamy, T. Pullaiah, Zhe-Sheng Chen, 2021-10-08 Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis and anticancer activities. In addition, biotechnological methods, including cell cultures, the use of bioreactors and metabolic engineering strategies to improve Paclitaxel production are also discussed. The book discusses topics such as mechanisms of action against cancer, novel forms of Paclitaxel for an effective cancer treatment, strategies for enhancing its bioavailability, and the application of nanocarriers for its delivery and chemotherapy of cancer. This is a valuable resource for cancer researchers, biotechnologists and members of biomedical field who are interested in the promising anticancer qualities of this antineoplastic drug and how to enhance them for better treatments. - Presents detailed information about Paclitaxel research, from its discovery to clinical uses and biotechnological routes of commercial production - Focuses on Paclitaxel development as an effective chemotherapeutic drug, along with its application in different types of cancers - Encompasses descriptive illustrations and workflows to help the reader fully understand the content and easily apply it to their research |
| cancer discovery impact factor 2022: Biosensor Based Advanced Cancer Diagnostics Raju Khan, Arpana Parihar, S.K. Sanghi, 2021-08-25 Early diagnosis of cancer and other non-oncological disorders gives a significant advantage for curing the disease and improving patient's life expectancy. Recent advances in biosensor-based techniques which are designed for specific biomarkers can be exploited for early diagnosis of diseases. Biosensor Based Advanced Cancer Diagnostics covers all available biosensor-based approaches and comprehensive technologies; along with their application in diagnosis, prognosis and therapeutic management of various oncological disorders. Besides this, current challenges and future aspects of these diagnostic approaches have also been discussed. This book offers a view of recent advances and is also helpful for designing new biosensor-based technologies in the field of medical science, engineering and biomedical technology. Biosensor Based Advanced Cancer Diagnostics helps biomedical engineers, researchers, molecular biologists, oncologists and clinicians with the development of point of care devices for disease diagnostics and prognostics. It also provides information on developing user friendly, sensitive, stable, accurate, low cost and minimally invasive modalities which can be adopted from lab to clinics. This book covers in-depth knowledge of disease biomarkers that can be exploited for designing and development of a range of biosensors. The editors have summarized the potential cancer biomarkers and methodology for their detection, plus transferring the developed system to clinical application by miniaturization and required integration with microfluidic systems. - Covers design and development of advanced platforms for rapid diagnosis of cancerous biomarkers - Takes a multidisciplinary approach to sensitive transducers development, nano-enabled advanced imaging, miniaturized analytical systems, and device packaging for point-of-care applications - Offers an insight into how to develop cost-effective diagnostics for early detection of cancer |
| cancer discovery impact factor 2022: The Genetics of Cancer B.A. Ponder, M.J. Waring, 2012-12-06 It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in The Genetics of Cancer illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications. |
| cancer discovery impact factor 2022: Cancer and Society Eric H. Bernicker, 2019-03-04 While a number of books have looked at the intersection between human health in general and other topics, such as climate change or diet, this book focuses specifically on cancer as it impacts and is impacted by social justice issues. The massive explosion of research knowledge of cancer immunology and genomics is holding out great promise of therapeutic advances, yet other human actions—climate change, pollution, business decisions, advertising – are fostering health inequalities as well as increasing risks. Those involved in cancer care and research are in a unique position to let their experiences and knowledge inform the public, yet very often have not taken strong public roles when it comes to discussing issues surrounding tobacco, climate change and health risks, financial toxicity of treatments, and diet choices. Written by a multidisciplinary team of authors and for medical oncologists, cancer researchers, occupational health workers, and related medical students, residents, and fellows, this book encourages oncologists to address public health care and the societal issues associated with cancer risk. This volume discusses the overarching theme of environmental justice and oncology, focuses on business and cancer (such as clinical trials, drug development and profits, and global disparities), as well as animals and cancer. |
| cancer discovery impact factor 2022: Natural Products for Cancer Prevention and Therapy Anupam Bishayee, Mukerrem Betul Yerer-Aycan, 2018-11-07 This book is a printed edition of the Special Issue Natural Products for Cancer Prevention and Therapy that was published in Nutrients |
| cancer discovery impact factor 2022: Tropical Diseases Bulletin , 1958 |
| cancer discovery impact factor 2022: Network Pharmacology Shao Li, 2021-09-29 This book introduces “network pharmacology” as an emerging frontier subject of systematic drug research in the era of artificial intelligence and big data. Network Pharmacology is an original subject of fusion system biology, bioinformatics, network science and other related disciplines. It emphasizes on starting from the overall perspective of the system level and biological networks, the analysis of the laws of molecular association between drugs and their treatment objects, reveals the systematic pharmacological mechanisms of drugs, and guides the research and development of new drugs and clinical diagnosis and treatment. After it was proposed, network pharmacology has been paid attention by researchers, and it has been rapidly developed and widely used. In order to systematically reveal the biological basis of diagnosis and treatment in traditional Chinese medicine and modern medicine, we proposed a new concept of network target for the first time, which has become the core theory of network pharmacology. The core principle of a network target is to construct a biological network that can be used to decipher complex diseases. The network is then used as the therapeutic target, to which multicomponent remedies are applied. This book mainly includes four parts: 1) The concept and theory of network pharmacology; 2) Common analysis methods, databases and software in network pharmacological research; 3) Typical cases of traditional Chinese medicine modernization and modern drug research based on network pharmacology; 4) Network pharmacology practice process based on drugs and diseases. |
| cancer discovery impact factor 2022: Drug Repurposing in Cancer Therapy Kenneth K.W. To, William C.S. Cho, 2020-07-29 Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy. Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource. - Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research - Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences - Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types |
| cancer discovery impact factor 2022: Childhood Acute Lymphoblastic Leukemia Ajay Vora, 2017-04-21 This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia. |
| cancer discovery impact factor 2022: Pain Management and the Opioid Epidemic National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, 2017-09-28 Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring. |
| cancer discovery impact factor 2022: Beyond the HIPAA Privacy Rule Institute of Medicine, Board on Health Care Services, Board on Health Sciences Policy, Committee on Health Research and the Privacy of Health Information: The HIPAA Privacy Rule, 2009-03-24 In the realm of health care, privacy protections are needed to preserve patients' dignity and prevent possible harms. Ten years ago, to address these concerns as well as set guidelines for ethical health research, Congress called for a set of federal standards now known as the HIPAA Privacy Rule. In its 2009 report, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research, the Institute of Medicine's Committee on Health Research and the Privacy of Health Information concludes that the HIPAA Privacy Rule does not protect privacy as well as it should, and that it impedes important health research. |
| cancer discovery impact factor 2022: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| cancer discovery impact factor 2022: The Metric Tide James Wilsdon, 2016-01-20 ‘Represents the culmination of an 18-month-long project that aims to be the definitive review of this important topic. Accompanied by a scholarly literature review, some new analysis, and a wealth of evidence and insight... the report is a tour de force; a once-in-a-generation opportunity to take stock.’ – Dr Steven Hill, Head of Policy, HEFCE, LSE Impact of Social Sciences Blog ‘A must-read if you are interested in having a deeper understanding of research culture, management issues and the range of information we have on this field. It should be disseminated and discussed within institutions, disciplines and other sites of research collaboration.’ – Dr Meera Sabaratnam, Lecturer in International Relations at the School of Oriental and African Studies, University of London, LSE Impact of Social Sciences Blog Metrics evoke a mixed reaction from the research community. A commitment to using data and evidence to inform decisions makes many of us sympathetic, even enthusiastic, about the prospect of granular, real-time analysis of our own activities. Yet we only have to look around us at the blunt use of metrics to be reminded of the pitfalls. Metrics hold real power: they are constitutive of values, identities and livelihoods. How to exercise that power to positive ends is the focus of this book. Using extensive evidence-gathering, analysis and consultation, the authors take a thorough look at potential uses and limitations of research metrics and indicators. They explore the use of metrics across different disciplines, assess their potential contribution to the development of research excellence and impact and consider the changing ways in which universities are using quantitative indicators in their management systems. Finally, they consider the negative or unintended effects of metrics on various aspects of research culture. Including an updated introduction from James Wilsdon, the book proposes a framework for responsible metrics and makes a series of targeted recommendations to show how responsible metrics can be applied in research management, by funders, and in the next cycle of the Research Excellence Framework. The metric tide is certainly rising. Unlike King Canute, we have the agency and opportunity – and in this book, a serious body of evidence – to influence how it washes through higher education and research. |
| cancer discovery impact factor 2022: Global Trends 2040 National Intelligence Council, 2021-03 The ongoing COVID-19 pandemic marks the most significant, singular global disruption since World War II, with health, economic, political, and security implications that will ripple for years to come. -Global Trends 2040 (2021) Global Trends 2040-A More Contested World (2021), released by the US National Intelligence Council, is the latest report in its series of reports starting in 1997 about megatrends and the world's future. This report, strongly influenced by the COVID-19 pandemic, paints a bleak picture of the future and describes a contested, fragmented and turbulent world. It specifically discusses the four main trends that will shape tomorrow's world: - Demographics-by 2040, 1.4 billion people will be added mostly in Africa and South Asia. - Economics-increased government debt and concentrated economic power will escalate problems for the poor and middleclass. - Climate-a hotter world will increase water, food, and health insecurity. - Technology-the emergence of new technologies could both solve and cause problems for human life. Students of trends, policymakers, entrepreneurs, academics, journalists and anyone eager for a glimpse into the next decades, will find this report, with colored graphs, essential reading. |
| cancer discovery impact factor 2022: Transforming Clinical Research in the United States Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2010-10-22 An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise. |
| cancer discovery impact factor 2022: Adenocarcinoma of the Prostate Andrew W. Bruce, John Trachtenberg, 2012-12-06 Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book. |
| cancer discovery impact factor 2022: Cancer Medicine James F. Holland, 1997 |
| cancer discovery impact factor 2022: Cellular and Molecular Immunology Abul K. Abbas, Andrew H. Lichtman, 2005 The 5th Edition of this comprehensive title continues the tradition of delivering an accessible, engaging, and current introduction to this essential subject. The authors describe the principles of basic and applied immunology in a concise, straightforward manner, while incorporating the most up-to-date information. Over 400 illustrations help readers quickly and easily grasp key concepts. The entire text has been revised and includes new information about the organization of lymphoid organs and the mechanisms of innate immunity. (Midwest). |
| cancer discovery impact factor 2022: Progress against cancer Education U.S. Department of Health (and Welfare), National Advisory Cancer Council (U.S.), 1962 |
| cancer discovery impact factor 2022: Contrast-Enhanced Digital Mammography (CEDM) Jacopo Nori, Maninderpal Kaur, 2018-10-09 This book offers a comprehensive, practical resource entirely devoted to Contrast-Enhanced Digital Mammography (CEDM), a state-of-the-art technique that has emerged as a valuable addition to conventional imaging modalities in the detection of primary and recurrent breast cancer, and as an important preoperative staging tool for women with breast cancer. CEDM is a relatively new breast imaging technique based on dual energy acquisition, combining mammography with iodine-based contrast agents to display contrast uptake in breast lesions. It improves the sensitivity and specificity of breast cancer detection by providing higher foci to breast-gland contrast and better lesion delineation than digital mammography. Preliminary results suggest that CEDM is comparable to breast MRI for evaluating the extent and size of lesions and detecting multifocal lesions, and thus has the potential to become a readily available, fast and cost-effective examination. With a focus on the basic imaging principles of CEDM, this book takes a practical approach to breast imaging. Drawing on the editors’ and authors’ practical experience, it guides the reader through the basics of CEDM, making it especially accessible for beginners. By presenting the key aspects of CEDM in a straightforward manner and supported by clear images, the book represents a valuable guide for all practicing radiologists, in particular those who perform breast imaging and have recently incorporated or plan to incorporate CEDM into their diagnostic arsenal. |
| cancer discovery impact factor 2022: Guide for the Care and Use of Laboratory Animals National Research Council, Division on Earth and Life Studies, Institute for Laboratory Animal Research, Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011-01-27 A respected resource for decades, the Guide for the Care and Use of Laboratory Animals has been updated by a committee of experts, taking into consideration input from the scientific and laboratory animal communities and the public at large. The Guide incorporates new scientific information on common laboratory animals, including aquatic species, and includes extensive references. It is organized around major components of animal use: Key concepts of animal care and use. The Guide sets the framework for the humane care and use of laboratory animals. Animal care and use program. The Guide discusses the concept of a broad Program of Animal Care and Use, including roles and responsibilities of the Institutional Official, Attending Veterinarian and the Institutional Animal Care and Use Committee. Animal environment, husbandry, and management. A chapter on this topic is now divided into sections on terrestrial and aquatic animals and provides recommendations for housing and environment, husbandry, behavioral and population management, and more. Veterinary care. The Guide discusses veterinary care and the responsibilities of the Attending Veterinarian. It includes recommendations on animal procurement and transportation, preventive medicine (including animal biosecurity), and clinical care and management. The Guide addresses distress and pain recognition and relief, and issues surrounding euthanasia. Physical plant. The Guide identifies design issues, providing construction guidelines for functional areas; considerations such as drainage, vibration and noise control, and environmental monitoring; and specialized facilities for animal housing and research needs. The Guide for the Care and Use of Laboratory Animals provides a framework for the judgments required in the management of animal facilities. This updated and expanded resource of proven value will be important to scientists and researchers, veterinarians, animal care personnel, facilities managers, institutional administrators, policy makers involved in research issues, and animal welfare advocates. |
| cancer discovery impact factor 2022: Epigenetic and Metabolic Regulators of Breast Carcinogenesis Iman Mamdouh Talaat, Maha Mohamed Saber-Ayad, Hauke Busch, Noha Mousaad Elemam, 2024-07-23 Breast cancer is the most common tumor in females worldwide. Cancer epigenetics and metabolic reprogramming are known cancer hallmarks. Recent advances in the field of epigenetics include histone modification, DNA methylation, and non-coding RNAs. In contrast to genetic modifications, epigenetics refers to a set of dynamic alterations. By controlling the on and off states of oncogenes and tumor suppressor genes, as well as re-engineering the tumor microenvironment, epigenetics plays a crucial role in the initiation and progression of carcinogenesis. Additionally, the complex process of metabolic reprogramming is required for both malignant transformation and tumor development, including invasion and metastasis. Furthermore, reprogrammed metabolic activities have been utilized to diagnose, monitor, and treat cancer patients. In tumor tissues, metabolic heterogeneity was found to take a role in the adaptation to the microenvironment drastic changes resulting from current therapeutic modalities. |
| cancer discovery impact factor 2022: Biomarkers and Immunotherapy for Genitourinary Tumors Hui Dai, Jun Pang, Yu Fan, Jianzhong Ai, Youqiang Ke, Lu Yang, 2024-04-02 Genitourinary tumors consist of a large variety of malignancies located in the urinary and the reproductive systems, mainly including prostate cancer, bladder cancer, and renal tumors. Apart from surgeries, various systemic treatments have been used for the whole-course management of genitourinary tumors, including radiation therapy, chemotherapy, and hormonal therapy. However, the characteristics of progression, metastasis, and drug resistance deriving from tumors require and breed novel treatments. Furthermore, exploring biomarkers of genitourinary tumors at the early stage is also beneficial to strengthen the management of patients with tumors. Additionally, the diagnostic and prognostic value of the potential biomarkers for immunotherapy and combined therapy of genitourinary tumors are underexplored. On the basis of precision treatments, the advent of immune-based therapies, including immune checkpoint inhibitors (ICIs, antibodies targeting PD-L1 /PD-1 and CTLA-4 pathways), tumor vaccines, and other therapies, has extended the scope of treatment modalities. FDA has until now approved the clinical application of immune checkpoint inhibitors in a wide range of diseases including some types of genitourinary tumors, whereas not all patients with genitourinary tumors are suitable for immune-based therapies, therefore, the understanding of its underlying mechanism is key to develop effective treatments based on current ICI-based immunotherapy. |
| cancer discovery impact factor 2022: Metastatic Tumor Growth Gesellschaft zur Bekämpfung der Krebskrankheiten Nordrhein-Westfalen, 1980 |
| cancer discovery impact factor 2022: WHO Global Report on Traditional and Complementary Medicine 2019 World Health Organization, 2019-05-16 This report is structured in five parts: national framework for traditional and complementary medicine (T&CM); product regulation; practices and practitioners; the challenges faced by countries; and finally the country profiles. Apart from the section on practices and practitioners the report is consistent with the format of the report of the first global survey in order to provide a useful comparison. The section on practices and practitioners which covers providers education and health insurance is a new section incorporated to reflect the emerging trends in T&CM and to gather new information regarding these topics at a national level. All new information received has been incorporated into individual country profiles and data graphs. The report captures the three phases of progress made by Member States; that is before and after the first WHO Traditional Medicine Strategy (1999?2005) from the first global survey to the second global survey (2005?2012) and from the second survey to the most recent timeline (2012?2018). |
| cancer discovery impact factor 2022: Post-Covid Rehabilitation, An Issue of Physical Medicine and Rehabilitation Clinics of North America, E-Book Monica Verduzco Gutierrez, 2023-07-10 In this issue, guest editors bring their considerable expertise to this important topic. - Contains 15 practice-oriented topics including what are post-COVID conditions and the burden of disease?; inpatient rehabilitation issues related to COVID-19; the role of surgical prehabilitation in the COVID-19 pandemic era and beyond; addressing rehabilitation healthcare disparities during the COVID-19 pandemic and beyond; and more. - Provides in-depth clinical reviews of post-COVID rehabilitation, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| cancer discovery impact factor 2022: The Longevity Diet Valter Longo, 2018-02-08 Live healthier for longer with the international bestselling guide that will change your life 'The diet that holds the key to staying young . . . Dr Valter Longo is now considered one of the most influential voices in the 'fasting movement' The Times 'Dr Valter Longo is one of the real scientific pioneers when it comes to researching the impact of food on health' Dr Michael Mosley, bestselling author of The Fast Diet and The Clever Guts Diet ________ This is the clinically tested, revolutionary and straightforward diet to help you slow-down ageing, fight disease and lose weight. Following 30 years of research, Professor Valter Longo - a biochemist and one of the world's leading researchers into ageing - discovered that the secret of longevity lies in cellular regeneration triggered by a special diet. And that by adhering to his fasting-mimicking diet, we can heal ourselves through food. The Longevity Diet will guide you through the process with: - An easy-to-adopt lifetime plan - Fasting-mimicking diet 3-4 times a year, just 5 days at a time - 30 easy and delicious recipes based on Longo's 'Five Pillars of Longevity' In this lifelong, health-boosting plan, you will feel the benefits of fasting without the hunger and live a longer, healthier and more fulfilled life. And you'll get to try easy, plant-and-fish based recipes . . . - Great for the heart and rich in antioxidants: black rice with courgette and shrimp - For a good source of iron, snack on dark chocolate and yoghurt - For dessert try tangy dried cranberries and walnuts ________ Make simple changes that can extend your healthy lifespan * Prevent age-related muscle and bone loss * Build your resistance to diabetes, cardiovascular disease, Alzheimer's and cancer * Maintain your ideal weight and reduce abdominal fat |
| cancer discovery impact factor 2022: Kinase Drug Discovery Richard A. Ward, Frederick Goldberg, 2012 Kinase drug discovery remains an area of significant interest across academia and in the pharmaceutical industry. There are now around 13 FDA approved small molecule drugs which target kinases and many more compounds in various stages of clinical development. Although there have been a number of reviews/publications on kinase research, this book fills a gap in the literature by considering the current and future opportunities and challenges in targeting this important family of enzymes. The book is forward-looking and identifies a number of hot topics and key areas for kinase drug discovery over the coming years. It includes contributions from highly respected authors with a combined experience in the industry of well over 200 years, which has resulted in a book of great interest to the kinase field and across drug discovery more generally. Readers will gain a real insight into the huge challenges and opportunities which this target class has presented drug discovery scientists. The many chapters cover a wide breadth of topics, are well written and include high quality colour and black and white images. Topics covered include an outline of how medicinal chemistry has been able to specifically exploit this unique target class, along with reflections on the mechanisms of kinases inhibitors. Also covered is resistance to kinase inhibitors caused by amino acid mutations, case studies of kinase programs and reviews areas beyond protein kinases and beyond the human kinome. Also described are modern approaches to finding kinase leads and the book finishes with a reflection of how kinase drug discovery may progress over the coming years. |
| cancer discovery impact factor 2022: The COVID-19 Catastrophe Richard Horton, 2020-07-13 The global response to the COVID-19 pandemic is the greatest science policy failure in a generation. We knew this was coming. Warnings about the threat of a new pandemic have been made repeatedly since the 1980s and it was clear in January that a dangerous new virus was causing a devastating human tragedy in China. And yet the world ignored the warnings. Why? In this short and hard-hitting book, Richard Horton, editor of the medical journal The Lancet, scrutinizes the actions that governments around the world took – and failed to take – as the virus spread from its origins in Wuhan to the global pandemic that it is today. He shows that many Western governments and their scientific advisors made assumptions about the virus and its lethality that turned out to be mistaken. Valuable time was lost while the virus spread unchecked, leaving health systems unprepared for the avalanche of infections that followed. Drawing on his own scientific and medical expertise, Horton outlines the measures that need to be put in place, at both national and international levels, to prevent this kind of catastrophe from happening again. Were supposed to be living in an era where human beings have become the dominant influence on the environment, but COVID-19 has revealed the fragility of our societies and the speed with which our systems can come crashing down. We need to learn the lessons of this pandemic and we need to learn them fast because the next pandemic may arrive sooner than we think. |
| cancer discovery impact factor 2022: Pulmonary Metastasis Leonard Weiss, Harvey A. Gilbert, 1978 |
| cancer discovery impact factor 2022: Genetics of Colorectal Cancer John D. Potter, Noralane M. Lindor, 2008-12-08 Genetic susceptibility refers to how variations in a person’s genes increase or decrease his or her susceptibility to environmental factors, such as chemicals, radiation and lifestyle (diet and smoking). This volume will explore the latest findings in the area of genetic susceptibility to gastrointestinal cancers, focusing on molecular epidemiology, DNA repair, and gene-environment interactions to identify factors that affect the incidence of GI cancers. Topics will include germline susceptibility, including Mendelian patterns of inheritance and gene-environment interactions that lead to cancer etiology. |
| cancer discovery impact factor 2022: Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes Robb Hollis, Mihaela Carmen Cristea , Mignon Van Gent, 2024-10-22 Ovarian cancer is an umbrella term for a collection of distinct disease entities (histotypes). Until now, the majority of research has focussed on the most common histotype, high-grade serous ovarian carcinoma (HGSOC), which accounts for 70% of cases. The less common histotypes – including endometrioid, clear cell, mucinous, low-grade serous, carcinosarcoma, and non-epithelial histotypes – have received far less research attention. Accordingly, while major advances in our understanding of HGSOC have led to molecularly-directed therapies that improve patient outcomes, progress in less common histotypes has lagged behind. Notably, many of the uncommon histotypes demonstrate resistance to conventional chemotherapy regimens, and their inherent biological differences suggest most are unlikely to respond to emerging molecular therapeutics designed to target the biology of common ovarian cancer types. |
| cancer discovery impact factor 2022: Women in Cancer Molecular Targets and Therapeutics, Volume II: 2022 Cinzia Lanzi, Ioana Berindan Neagoe, 2023-07-26 |
| cancer discovery impact factor 2022: Methods in gastrointestinal cancers Shuyun Rao, Imayavaramban Lakshmanan, Shantibhusan Senapati, Zhendong Jin, 2023-05-16 |
| cancer discovery impact factor 2022: Linking cellular metabolism to hematological malignancies, volume II Jian Yu, Manoj Kumar Kashyap, Zhizhuang Joe Zhao, Hubing Shi, 2024-04-18 |
